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Associate Editor's comments 
 
The reviewer recommend some rewording of your manuscript. The most important editing concerns the cause 
and effect relationship and the conclusions drawn from your data. Given the limitations of your experiments 
and the mysterious nature of some results, you must qualify and not over-state your conclusions. We would 
allow you to speculate what types of additional experiments are important for a better understanding of the 
mechanisms for the observed effects of K266 mutation. 
 
Thank you for the opportunity to send a revised version of our manuscript.  
Following the reviewers suggestions we have modified the title of the manuscript and introduced some 
changes in the Abstract and Discussion with the goal of avoiding overstating our conclusions. Changes are 
detailed below. Also, in answering comments by reviewer #2, we have tried to clarify that at no point in the 
manuscript do we propose that HSD2 SUMOylation could be the main protective mechanism limiting MR 
activation by glucocorticoids. Our data does not contradict all the data showing that impaired cortisol to 
cortisone conversion is what causes the syndrome of Apparent Mineralocorticoid Excess.  
Finally, we believe that our Discussion already points towards specific lines of research that could lead to a 
better understanding of the observed effects of mutant K266. Specifically: a) detailed study of MR and HSD2 
interactome (lines 410-423); b) determining whether HSD2 is situated near the nuclear pore and in that case 
disrupting that specific localization (lines 424-431); c) structural analysis of  differential MR conformational 
changes in response to different ligands and in the presence or absence of SUMOylated HSD2 (lines 432-
439). 
 
Reviewers' comments 
 
Reviewer #1: The authors should be commended for their careful revision and inclusion of additional 
experimental data. The new Figure 3 lends much stronger support for SUMOylation of HSD2. 
The manuscript is well written and provides novel information. The revision has improved the manuscript 
significantly and strengthened it. 
There are just a few suggestions to alter the text to make the manuscript fully consistent with the revised focus 
on localization. 
 
We would like to thank the reviewer for these comments. Please see our answers to your specific points 
below.  
 
1) I would suggest modifying the title to remove indications of 11β-HSD2 SUMOylation dependent changes in 
MR transactivation. 
 
Some possibilities could be: 
 
11β-HSD2 SUMOylation Modulates Cortisol-induced Mineralocorticoid Receptor Nuclear 
Translocation Independently of Effects on Transactivation 
 
11β-HSD2 SUMOylation Modulates Cortisol-induced Mineralocorticoid Receptor Nuclear 
Translocation but not its ability to limit Transactivation 
 
11β-HSD2 SUMOylation Dissociates Cortisol-induced Mineralocorticoid Receptor Nuclear 
Translocation from Transactivation 
 
We have modified the title using the first possibility suggested by the reviewer. 
 
2) the following two changes are strongly suggested: 
 
Line 385: change: 
 
" only 11β-HSD2 that has been SUMOylated appears to be" 
to: 
Point-by Point Rebuttal
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"only 11β-HSD2 that can be SUMOylated appears to be" 
 
(There is no evidence that it is only the SUMOylated fraction that is responsible for the effect. The modified 
text keeps options open) 
 
This line of text has been modified as suggested. 
 
Lines 443 to 446: 
 
Should be replaced with something similar to: 
 
"Interestingly, although impairing HSD2 SUMOylation enhances MR nuclear localization, it does not alter its 
ability to limit cortisol mediated cofactor recruitment to the receptor or to modulate its transcriptional 
activity. This phenomenon uncovers a complex and SUMOylation-regulated functional role of 11β-HSD2 that 
dissociates glucocorticoid-dependent MR subcellular localization from transcriptional activity." 
 
We have replaced the text in lines 443-446 with a paragraph similar to the one suggested by the reviewer. The 
text now reads “Interestingly, although impairing 11β-HSD2 SUMOylation enhances cortisol-dependent MR 
nuclear translocation, the amount of MR/co-activator complexes formed remains unaltered, resulting in the 
same transcriptional activity. This phenomenon uncovers a complex and SUMOylation-regulated functional 
role of 11β-HSD2 that dissociates glucocorticoid-dependent MR subcellular localization from transcriptional 
activity”. 
 
 
Reviewer #2: It is clear that the authors have worked hard to respond to the comments of the referees. 
However I remain concerned at the statement that 'taken together, our data demonstrate that SUMOylation of 
11β-HSD2 at residue K266 controls cortisol mediated MR nuclear translocation'. 
 
We have modified this statement, which now reads, “Taken together, our data suggests that SUMOylation of 
11β-HSD2 at residue K266 modulates cortisol-mediated MR nuclear translocation independently of effects on 
transactivation”. 
 
As the authors indicate in their response 'so far no syndrome of mineralocorticoid excess-associated mutation 
affecting residue K266 has been described.' This must be one of the acid tests of their hypothesis. By way of 
contrast a series of mutations of 11β-HSD2 have been described producing the Syndrome of 
Mineralocorticoid Excess (SAME) and are closely linked to the failure of inactivation of cortisol. 
 
We are fully convinced that failure of inactivation of cortisol is the basis of SAME, as indicated in the 
Introduction. Our data shows that lack of HSD2 SUMOylation (either by mutation of K266 residue or by 
enzymatic deSUMOylation) facilitates cortisol-induced MR nuclear translocation. However, this does not 
translate in increased transcriptional activity. Therefore, we do not expect this increased nuclear MR 
abundance would produce SAME. However, we do point out (Discussion, lines 378-382) that mutation 
K266R produces a mild change in HSD2 enzymatic activity, reminiscent of the effect of mutation R279C 
found in mild cases of SAME in humans. Based on this, we cannot fully discard the possibility that mutations 
in residue K266 could theoretically produce some form of SAME. Since this is not supported by data from 
clinical genetics, we would like to avoid overstating this possibility.  
 
The authors go on to state: 
'With the current data we cannot predict whether a defect in SUMOylation would produce SAME.' If 
SUMOylation is the mechanism that controls cortisol-mediated MR nuclear translocation then this would be 
expected. 
 
See answer to the point above.  
 
There appears to be an error on page 4. The authors state: 
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'We do not believe that SUMOylation and not cortisol to cortisone conversion is the main protective 
mechanism.' I presume they mean 'We believe that SUMOylation and not cortisol to cortisone conversion is 
the main protective mechanism.' 
 
We apologize for not being sufficiently clear in our previous answer to the reviewer´s comments. As we have 
indicated in the manuscript and also in the current rebuttal, it is clear to us that SAME arises from lack of 
efficient conversion of cortisol to cortisone by HSD2. As explained above, we now show that HSD2 
SUMOylation is important to control cortisol-induced MR nuclear translocation, but this does not result in 
increased receptor activity. Therefore, we conclude that SUMOylation per se is not the main protective 
mechanism. However, since mutant K266R shows a mild change in enzymatic activity, it is still possible that 
this could produce a slightly impaired cortisol to cortisone conversion in vivo. Our current data does not allow 
to test this possibility.  
 
In summary I believe that it is reasonable for the authors to state that lack of SUMOylation of 11β-HSD2 at 
residue K266 results in cortisol mediated MR nuclear translocation. The importance of this mechanism in 
controlling the normal specificity of the MR remains to be determined. It is also unclear if defects of 
SUMOylation can produce a syndrome of apparent mineralocorticoid excess. 
 
We fully agree with this summary. We believe that in its current form the manuscript presents this view of the 
data. 
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Abstract 26 
The enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) has an essential role in aldosterone 27 
target tissues, conferring aldosterone selectivity for the mineralocorticoid receptor (MR) by converting 28 
11β-hydroxyglucocorticoids to inactive 11-ketosteroids. Congenital deficiency of 11β-HSD2 causes a 29 
form of salt-sensitive hypertension known as the syndrome of apparent mineralocorticoid excess. The 30 
disease phenotype, which ranges from mild to severe, correlates well with reduction in enzyme activity. 31 
Furthermore, polymorphisms in the 11-HSD2 coding gene (HSD11B2) have been linked to high blood 32 
pressure and salt-sensitivity, major cardiovascular risk factors. 11-HSD2 expression is controlled by 33 
different factors such as cytokines, sex steroids or vasopressin, but post-translational modulation of its 34 
activity has not been explored. Analysis of 11β-HSD2 sequence revealed a consensus site for conjugation 35 
of small ubiquitin-related modifier (SUMO) peptide, a major post-translational regulatory event in several 36 
cellular processes. Our results demonstrate that 11β-HSD2 is SUMOylated at lysine 266. Non-37 
SUMOylatable mutant K266R showed slightly higher substrate affinity and decreased Vmax, but no 38 
effects on protein stability or subcellular localization. Despite mild changes in enzyme activity, mutant 39 
K266R was unable to prevent cortisol-dependent MR nuclear translocation. The same effect was achieved 40 
by co-expression of wild-type 11-HSD2 with SENP1, a protease that catalyzes SUMO deconjugation. In 41 
the presence of 11β-HSD2-K266R increased nuclear MR localization did not correlate with increased 42 
response to cortisol or increased recruitment of transcriptional co-regulators. Taken together, our data 43 
suggests that SUMOylation of 11β-HSD2 at residue K266 modulates cortisol-mediated MR nuclear 44 
translocation independently of effects on transactivation. 45 
Précis 46 
Post-translational modification of 11β-hydroxysteroid dehydrogenase type 2 by SUMOylation at residue 47 
K266R has a key role in controlling MR subcellular localization in the presence of cortisol.  48 
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Introduction 49 
11β-hydroxysteroid dehydrogenase (11β-HSD)1 isozymes catalyze the interconversion between 50 
biologically active 11β-hydroxyglucocorticoids and inactive 11-ketosteroids (1). The isoform 11β-51 
hydroxysteroid dehydrogenase type 2 (11β-HSD2) catalyzes the NAD-dependent reaction to convert 52 
cortisol to inactive cortisone (2). The reverse reaction is NADPH-dependent and is catalyzed by the 53 
isozyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), leading to increased local cortisol 54 
concentration in tissues such as liver and adipose (3,4).  55 
11β-HSD2 is specifically expressed in aldosterone target tissues, such as epithelial cells from distal colon 56 
and principal cells of the distal nephron, and serves to protect the non-selective mineralocorticoid receptor 57 
(MR) from activation by glucocorticoids, which circulate at much higher concentration than aldosterone. 58 
11β-HSD2 confers aldosterone-specificity on MR and brings key physiological functions of electrolyte 59 
and volume homeostasis under the control of the renin-angiotensin system (RAS) (4). 60 
11β-HSD2 can be saturated by high cortisol levels due to cortisol hypersecretion, resulting in 61 
inappropriate MR activation (5,6). Similarly, decreased 11-HSD2 activity also leads to inappropriate 62 
activation of MR by endogenous glucocorticoids. In both situations, MR-target proteins, such as the 63 
epithelial sodium channel (ENaC) are uncoupled from the RAS leading to renal sodium retention and a 64 
salt-sensitive increase in blood pressure, both in humans (7) and in rodent models (8-10). This concept is 65 
illustrated by the syndrome of apparent mineralocorticoid excess (AME), characterized by hypertension, 66 
hypokalemia and low renin and aldosterone levels (11). AME can be congenital, due to loss-of-function 67 
mutations of the 11-HSD2 coding gene (HSD11B2) (12), or acquired, most commonly due to excessive 68 
consumption of natural licorice, which contains glycyrrhetinic acid that together with its derivative, 69 
carbenoxolone, inhibit 11β-HSD2 (13). In patients, the severity of AME symptoms correlates well with 70 
the underlying enzyme activity (14). Several polymorphisms in HSD11B2 correlate with slightly 71 
decreased 11-HSD2 activity and associate to salt-sensitive increase of blood pressure both in healthy 72 
volunteers and patients with essential hypertension (15-21). This evidence indicates that appropriate 73 
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control of 11-HSD2 expression and activity is essential for blood pressure regulation (22). Factors 74 
controlling 11-HSD2 expression are not fully defined, although there is evidence indicating 75 
transcriptional regulation by cytokines, sex steroids, vasopressin and microRNAs (1,23). However, 76 
cellular mechanisms that dynamically regulate 11β-HSD2, such as post-translational modifications have 77 
not been explored.  78 
Small ubiquitin-related modifiers (SUMO) are ~11 kDa polypeptides that are post-translationally 79 
conjugated to other proteins. This reversible post-translational modification is typically observed in 80 
nuclear proteins, related to transcription factor regulation (24), DNA damage response (25), mitosis or 81 
cell cycle progression (26). However, regulatory SUMOylation has also been described in cytosolic or 82 
plasma membrane proteins (27). Analysis of the human 11β-HSD2 sequence uncovered a canonical 83 
SUMOylation consensus motif around lysine 266 (Fig. 1). Based on that, we hypothesized that 84 
SUMOylation of K266 in 11β-HSD2 may be involved in regulating enzyme activity and therefore could 85 
affect MR glucocorticoid-dependent transcriptional activity. Our results show that 11β-HSD2 is 86 
SUMOylated at residue K266. Non-SUMOylatable mutant 11-HSD2, K266R, displays mild changes in 87 
enzymatic activity with slightly higher affinity but decreased Vmax and is unable to prevent cortisol-88 
dependent MR nuclear translocation. Paradoxically, increased MR nuclear localization in the presence of 89 
11β-HSD2-K266R does not correlate with enhanced activity in the presence of cortisol. Our results 90 
uncover a prominent role of 11β-HSD2 SUMOylation in controlling cortisol-dependent MR subcellular 91 
localization.  92 
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Experimental procedures 93 
Sequence analysis - We used the prediction algorithm GPS-SUMO (28) to search for consensus 94 
SUMOylation motifs (-K-x-D/E, where  is a large hydrophobic residue, K is the lysine conjugated to 95 
SUMO, x is any amino acid, and D or E is an acidic residue -Asp or Glu-) in 11-HSD2 from different 96 
species. Additionally, GPS-SUMO was used to predict putative SIMs in the same sequences. Multiple 97 
sequence comparison was performed with Clustal Omega (European Bioinformatics Institute).  98 
Plasmid constructs - Generation and use of functional fluorescent derivatives of MR with insertion of 99 
YFP or GFP after amino acid 147 (MR-147-YFP/GFP) has been previously described (29-31). Plasmid 100 
pcDNA3.1-MR, expressing hMR-WT was previously described (32). Plasmid expressing wild-type 101 
human 11β-HSD2 fused to FLAG epitope (11-HSD2-FLAG) cloned in pcDNA3 (Invitrogen) has been 102 
previously described (33). 11β-HSD2 coding sequence was amplified by PCR and subcloned in peCFP-103 
N1 vector (Clontech) to produce an in-frame fusion with the cyan fluorescent protein (CFP) (11-HSD2-104 
CFP). 11β-HSD2 non-SUMOylatable mutant K266R and AME mutants R337C (34) or R213C (35) were 105 
obtained upon introducing point mutations by site-directed mutagenesis using the Quickchange Lightning 106 
Kit (Agilent Technologies). Human SUMO1 cloned in pEYFP-C1 (Clontech) to express YFP-SUMO1 107 
was a gift from Dr. Edward Yeh (Addgene plasmid 13380) (36). Sequence of human deSUMOylase 108 
SENP1 cloned in pFlag-CMV (Sigma) to express epitope-tagged FLAG-SENP1 was obtained from 109 
Addgene collection (plasmid 17357) (37). SENP1 sequence was amplified by PCR and subcloned in 110 
pcDNA 3.1 (Invitrogen) to remove the FLAG epitope from the original construct in order to prevent 111 
cross-reactions PLA. Generation of a plasmid expressing HA-tagged steroid receptor co-activator 1 112 
(SRC-1) has been previously described (29). All constructs and mutations were confirmed by DNA 113 
sequencing. 114 
Cell culture, transfection and hormone treatment - We used COS-7 cells, which lack endogenous MR and 115 
GR expression (38). COS-7 cells were obtained from American Type Culture Collection (Manassas, VA) 116 
and maintained in DMEM supplemented with 10% FBS. Cells were regularly tested to ensure absence of 117 
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mycoplasma infection. Cells were transfected with Jetprime (Polyplus Transfection, Illkirch, France) as 118 
described before (29,30). pcDNA3.1 (Invitrogen) was used as a control in transfections. At the time of 119 
transfection cells were washed and transferred to growth medium supplemented with charcoal-stripped 120 
FBS (Lonza) to eliminate steroids. Twenty-four hours after transfection, cells were washed and treated 121 
with the indicated amounts of aldosterone or cortisol. Aldosterone and cortisol were obtained from Sigma, 122 
dissolved in ethanol, and added to cells to the final concentration indicated for each experiment. Control 123 
cells were treated with ethanol at the same dilution used for treatments (1:1000). 124 
Immunoprecipitation and western blot analysis - Immunoprecipitation of 11-HSD2 was performed using 125 
a mouse monoclonal antibody against FLAG epitope (Sigma) at 1:150 dilution in lysis buffer (in mM: 126 
NaCl, 170; EDTA, 1; DTT, 1; Tris-HCl, 20; pH 7.6) supplemented with 0.5% NonidetTM-P40 and a 127 
protease inhibitor cocktail (Roche). Antibody-antigen complex capture was performed using Proteome 128 
Protein A and Protein G Magnetic Beads kit (Millipore). Western blot analysis was performed as 129 
previously described (29,30). Human 11β-HSD2 was detected with rabbit polyclonal antibody (H-145, 130 
Santa Cruz Biotechnology; epitope corresponding to amino acids 261-405). MR was detected with mouse 131 
monoclonal antibody rMR365-4D6, developed by Dr. Celso Gomez-Sanchez et al. (39) and obtained 132 
from the Developmental Studies Hybridoma Bank (The University of Iowa, Department of Biology, Iowa 133 
City, IA). When indicated, fluorescent fusion proteins were detected using a polyclonal antibody raised in 134 
rabbit (Abcam), kindly provided by Dr. Raimundo Freire (40). To control for total protein loading we 135 
used monoclonal antibodies against GAPDH (Abcam) or β-actin (Sigma). Secondary antibodies 136 
conjugated with peroxidase (GE Healthcare) were used at 1:10000 dilution. Western blots were developed 137 
with Immun-Star WesternC kit (Bio-Rad) and signals were detected with a Chemidoc imaging system 138 
(Bio-Rad) and quantified with the software provided by the manufacturer (Image Lab, Bio-Rad). 139 
Cell imaging and kinetic analysis of nuclear translocation - Semiquantitative analysis of subcellular 140 
distribution in the absence of aldosterone was performed as previously described (41). Briefly, cells were 141 
transfected with the indicated combination of plasmids, grown for 48 hours in culture medium 142 
supplemented with charcoal-stripped serum. Cells were then fixed, mounted, and images were taken 143 
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under a confocal microscope. At least 75 cells per condition were scored into five categories (N, exclusive 144 
nuclear localization; N > C, predominant nuclear localization; N = C, even distribution throughout cytosol 145 
and nucleus; N < C, predominant cytosolic localization; C, exclusive cytosolic localization). Data are 146 
shown as the percentage of cells in each category from the total amount of cells scored. Images were 147 
collected using a Fluoview 1000 confocal microscope (Olympus, Barcelona, Spain). Kinetic analysis of 148 
cortisol-induced MR nuclear translocation was performed as previously described (30,42). Briefly, cells 149 
were transfected with MR-147-GFP and grown for 48 hours in DMEM supplemented with charcoal-150 
stripped FBS. Cells were then transferred to extracellular saline (in mM: NaCl, 137; KCl, 4; CaCl2, 1.8; 151 
MgCl2, 1; glucose, 10; HEPES,10; pH 7.4), placed under a Fluoview 1000 confocal microscope 152 
(Olympus) in a temperature-controlled environmental chamber set at 37°C and treated by adding 10 nM 153 
aldosterone to the medium. Images were collected for 60 minutes at a sampling rate of one every 2 154 
minutes. Quantitative analysis of MR-GFP distribution was performed frame-by-frame using the 155 
manufacturer´s software (Olympus). Recordings in the absence of aldosterone were performed to control 156 
for photobleaching of GFP. Data processing and sigmoid curve-fitting were performed using Prism 5 157 
(GraphPad) according to the following equation: 158 
 159 
𝐹 = 𝐹0 + [
𝐹𝑚𝑎𝑥−𝐹0
1+exp(
𝑡1/2−𝑡
𝑉𝑛
)
]  Equation 1 160 
 161 
where F0 is the initial nuclear fluorescence, Fmax is the maximal nuclear fluorescence reached, t1/2 is the 162 
time (min) at which fluorescence is halfway between F0 and Fmax, and Vn is a factor determining how 163 
steeply nuclear accumulation changes with time. 164 
In situ proximity ligation assay (PLA) - PLA was performed using a commercially available kit (Duolink, 165 
Olink Biosciences, Uppsala, Sweden) as described (29,30). 11β-HSD2 SUMOylation was detected in 166 
COS-7 cells transfected with WT or K266R 11-HSD2-FLAG and YFP-SUMO1 by using a mouse 167 
monoclonal anti-FLAG antibody (clone M2, Sigma) and a rabbit polyclonal anti-GFP (Abcam). MR 168 
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nuclear interaction with SRC-1 coactivator was detected in COS-7 cells transfected with WT MR and 169 
SRC-1-HA by using a mouse monoclonal anti-HA antibody (clone HA.11, Covance) and a rabbit 170 
polyclonal anti-MR (MR-H300, Santa Cruz Biotechnology). The antibodies used in the assay were 171 
previously validated by immunocytochemistry using previously described procedures (31,41). Specificity 172 
controls consisted of non-transfected cells, cells where one of the transfected plasmids was omitted or 173 
cells not treated with MR ligand. Results were quantified using the software provided by the manufacturer 174 
(Duolink Image Tool) and are expressed as average number of puncta per cell area. 175 
Transactivation function assays - MR transcriptional activity was assayed by co-transfecting a plasmid 176 
encoding MR with a plasmid containing a synthetic promoter containing two copies of the basic 177 
glucocorticoid-response element (GRE) fused to the firefly luciferase gene (GRE2X-luc; kindly provided 178 
by Dr. Rainer Lanz), and a third plasmid containing Renilla luciferase under the control of a 179 
cytomegalovirus promoter (pSG5-ren; kindly provided by Dr. Fátima Gebauer), as previously described 180 
(29,30). 11-HSD2 constructs were included in the transfection mix as indicated in each experiment. 181 
Total amounts of transfected DNA were kept constant. Cotransfected Renilla and firefly luciferase 182 
activities were measured sequentially using a commercially available kit (Dual-Glo, Promega). MR-183 
dependent transcriptional activity was calculated as the ratio firefly luciferase/Renilla luciferase. Results 184 
are given as normalized average ± SE. EC50 values were calculated from normalized data fitted to a 185 
log(agonist) versus response equation with variable slope using Prism 5 (GraphPad Software). 186 
11-HSD2 activity assays - 11β-HSD2 enzyme activity was determined using COS-7 cells transfected 187 
with WT or non-SUMOylatable mutant K266R cDNAs. Cells were washed 24 h after transfection and 188 
then transferred to charcoal-stripped serum-supplemented DMEM. Cells were treated with the indicated 189 
time and cortisol concentration. Cells were collected for protein assay by the method of Bradford and 190 
medium was used to extract steroids in ethyl acetate (HPLC grade) for analysis by liquid chromatography 191 
and tandem mass spectrometry (LC-MS/MS). The organic layer was dried by heating at 60ºC under a 192 
nitrogen gas current. Steroids were then dissolved in mobile phase (30% acetonitrile) and analyzed by 193 
LC-MS/MS as per (43) to obtain the absolute amount of cortisol and cortisone present in the medium. 194 
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Negative control consisted on samples from non-transfected cells run in parallel. Enzyme activity was 195 
calculated as pmol of cortisone accumulation normalized by time and total amount of protein. In certain 196 
experiments we expressed the data as percentage conversion of cortisol to cortisone. Data were fitted to a 197 
Michaelis-Menten equation using Prism 5 software (GraphPad Software). 198 
Independently, 11β-HSD2 activity was analyzed by measuring 3H-corticosterone conversion into 3H-11-199 
dehydrocorticosterone by HPLC as described (44). Data were analyzed by measuring the percentage 200 
conversion of cortisol to cortisone. 201 
Statistical analysis - Statistical analysis was performed using Prism 5 software (GraphPad Software). 202 
Unpaired Student t test, one-way ANOVA followed by Dunn’s multiple comparison test as indicated in 203 
each Figure.  204 
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Results  205 
11β-HSD2 is SUMOylated at lysine 266  206 
We used the prediction algorithm GPS-SUMO (28) to investigate whether the human 11-HSD2 207 
sequence displays any consensus SUMOylation sites. Results showed that lysine 266 is part of a sequence 208 
matching the core SUMOylation consensus motif -K-x-D/E flanked by P and G residues (Fig. 1A), 209 
which conform a high probability SUMOylation site (45). This lysine and the SUMO consensus motif are 210 
highly conserved in other mammals including primates, ruminants and rodents, but not pigs (Fig. 1A). 211 
Mapping of this residue to a structural homology model of 11-HSD2, based on the crystal structure of 212 
11-HSD1 (46), shows that it lies on a -sheet exposed to the solution and away from the core of the 213 
enzyme containing the catalytic and co-factor binding sites (Fig. 1B). In addition to the canonical high 214 
probability covalent SUMOylation site surrounding K266, the algorithm predicted additional lower 215 
probability SUMOylation sites and SUMO interaction motifs (SIM), which may mediate non-covalent 216 
interaction with SUMO peptides (on-line supplemental information, Table S1).  217 
To establish experimentally whether 11-HSD2 is SUMOylated at residue K266, we co-transfected 218 
FLAG-tagged WT or K266R mutant 11β-HSD2 with YFP-SUMO1 to perform intramolecular in situ 219 
proximity ligation assay (PLA) in COS-7 cells. Immunostaining of transfected WT or mutant 11-HSD2 220 
shows similar distribution patterns consistent with the expected ER-associated localization (6), indicating 221 
that mutation K266R does not alter subcellular sorting of the enzyme (Fig. 2A). PLA results using anti-222 
FLAG and anti-YFP antibodies show a prominent signal suggesting WT 11-HSD2 SUMOylation in the 223 
cytosolic, ER-associated region (Fig. 2B), even though most of YFP-SUMO-1 protein localizes in the 224 
nucleus, as expected (36). PLA signal of non-SUMOylatable mutant K266R was strongly reduced to 225 
approximately 25% of the WT signal (Fig. 2B and 2C). Further support for 11-HSD2 SUMOylation was 226 
obtained by co-transfecting the established deSUMOylase Sentrin-specific protease 1 (SENP1) (47). PLA 227 
signal was drastically reduced by co-expression of SENP1 to approximately 20% of the signal (Fig. 2B 228 
and 2C). Non-transfected cells or omission of either one of the transfected plasmids resulted in the 229 
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absence of signal (Fig. 2B and 2C). These results are consistent with 11β-HSD2 SUMOylation, 230 
predominantly at K266 residue. 231 
To confirm 11-HSD2 SUMOylation at residue K266 and quantify the steady-state fraction of total 232 
enzyme showing this post-translational modification, we co-transfected COS-7 cells with either FLAG-233 
tagged, WT 11β-HSD2 or non-SUMOylatable mutant K266R with a plasmid expressing YFP-SUMO1. 234 
Western blot analysis of cell lysates demonstrates comparable expression levels for WT and mutant 11-235 
HSD2 as well as for YFP-SUMO1 (Fig. 3A). After immunoprecipitation of 11β-HSD2 with an anti-236 
FLAG antibody and electrophoresis under denaturing conditions, we performed western blots with anti-237 
YFP (to detect YFP-SUMO1) and anti-11-HSD2. Results obtained with anti-YFP antibody show bands 238 
migrating at approximately 80 kDa (Fig. 3B), which would be consistent with the predicted molecular 239 
mass of approximately 82.5 kDa resulting from the mass of 11-HSD2, YFP and SUMO1 (44, 27 and 240 
11.5 kDa, respectively). The signal was notably decreased in the case of K266R mutant, despite equal 241 
levels of total protein expression (Fig. 3A and 3B). Probing immunoprecipitation products with anti-11-242 
HSD2 recognized bands at the predicted 11-HSD2 molecular mass (44 kDa), indicating that both the 243 
WT and mutant forms were immunoprecipitated to comparable extents (Fig. 3C). In addition, longer 244 
exposure tf the blot allowed detecting a slower-migrating band (Fig. 3D), which coincides with the band 245 
detected by anti-YFP at approximately 80 kDa (Fig. 3B). Taken together, these results further support that 246 
11-HSD2 is SUMOylated and that the majority of the signal arises from modification of residue K266 247 
residue, consistently with results from PLA (Fig. 2). Interestingly, the larger, SUMOylated form of 11-248 
HSD2 is not detected when total protein is analyzed by western blot using the input sample (Fig. 3A). 249 
Also, when probing immunoprecipitation products with anti-11-HSD2 antibody the larger form of 11-250 
HSD2 requires longer exposure to be detected than the unmodified form (Fig. 3C and 3D) suggesting that 251 
a low proportion of the protein is SUMOylated in our experimental conditions. This is consistent with the 252 
general finding that the proportion of proteins modified by SUMO in vivo is very low, however the 253 
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modification usually has a high functional impact, a phenomenon that has been termed the “SUMO 254 
paradox” (48). 255 
SUMOylation alters 11-HSD2 enzyme kinetics but not protein abundance 256 
To assess whether SUMOylation at residue K266 alters 11-HSD2 enzyme abundance or activity, we 257 
transiently transfected WT or mutant 11-HSD2 in COS-7 cells, quantifying protein expression by 258 
western blot. Mutants R213C and R337C, which induce AME in humans, were included as controls.  259 
R213C is a loss-of-function mutation (12), while R337C is a destabilized variant of the protein (34,49). 260 
Quantification of 11-HSD2 expression in transfected cells showed that non-SUMOylatable mutant 261 
K266R or mutation R213C did not produce any significant change in protein abundance when compared 262 
to WT 11-HSD2 (Fig. 4). As expected, mutant R337C showed clearly diminished expression to 263 
approximately 20% of WT level (Fig. 4).  264 
In order to test whether mutation K266R alters 11β-HSD2 activity, we measured conversion of cortisol to 265 
cortisone in intact COS-7 cells transfected or not with 11-HSD2 variants by performing liquid 266 
chromatography coupled to mass spectrometry (LC-MS/MS) on cell extracts. First, we compared the 267 
time-dependent conversion of 300 nM cortisol to cortisone in non-transfected or WT 11-HSD2 268 
transfected cells (Fig. 5A). Results show a linear time-dependent cortisol conversion in cells transfected 269 
with WT 11-HSD2 and a very slow conversion in non-transfected cells (lower than 1% in up to 4 hours 270 
incubation; Fig. 5A). We then compared WT 11-HSD2 and non-SUMOylatable mutant K266R activity 271 
by incubating 30 minutes with increasing cortisol concentration and fitting the data to a Michaelis-Menten 272 
curve (Fig. 5B). We obtained a Km of 565  18  nM for WT and 377  13   for K266R mutant and a 273 
Vmax of 574  19 pmol/hour/mg of protein for WT and 395  4 for K266R mutant. The parameters 274 
calculated for WT 11-HSD2 are consistent with previously published data (35,49). Differences in 275 
enzyme parameters did not reflect differential expression of the 11-HSD2 constructs (Fig. 4).  276 
We used an independent method to assess 11β-HSD2 activity by measuring 3H-corticosterone conversion 277 
to 3H-11-dehydrocorticosterone by HPLC. COS-7 cells were treated with 10 nM 3H-corticosterone for 60 278 
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min and conversion to 3H-11-dehydrocorticosterone was measured and normalized to total protein 279 
content. WT 11-HSD2 showed a 12.24% ± 0.55 conversion (mean ± SE, n=6), while mutant K266R 280 
showed a 12.72% ± 0.43 conversion (n=6). 281 
Lack of SUMOylation at residue K266 allows cortisol-dependent MR nuclear translocation 282 
To investigate whether K266 SUMOylation has a role on 11β-HSD2 function in diminishing MR 283 
activation by glucocorticoids, we first asked whether mutant K266R affects 11β-HSD2 ability to prevent 284 
cortisol-induced MR nuclear translocation. To that end we studied nuclear translocation of our fully 285 
functional fluorescent derivative MR, with YFP inserted after amino acid 147 (29-31), cotransfected or 286 
not with different 11-HSD2 constructs fused to CFP (WT; AME loss-of-function mutant R337C; and 287 
non SUMOylatable mutant K266R). The assay was performed in COS-7 cells, which lack detectable 288 
endogenous expression of 11β-HSD2 (Figs. 2, 4 and 5). Transfected cells were left untreated or exposed 289 
overnight to two different physiological cortisol concentrations (100 or 500 nM). In the absence of ligand, 290 
MR localization is predominantly cytosolic in most (> 80%) of the cells (Fig. 6A and 6B) as previously 291 
described in the same cell line (50). Cotransfection with WT 11-HSD2, K266R or R337C did not alter 292 
naïve MR subcellular localization in the absence of cortisol (Fig. 6A and 6B). Overnight treatment with 293 
100 nM cortisol stimulated full MR translocation to the nucleus (> 90% of cells). WT 11-HSD2 294 
coexpression prevented MR translocation, keeping a predominantly cytosolic MR localization, consistent 295 
with the cortisol-inactivation function of the enzyme (Fig. 6C and 6D). Cotransfection of 11-HSD2-296 
R337C construct failed to prevent cortisol-induced MR translocation (Fig. 6C and 6D), consistent with 297 
the loss-of-function effect previously described for this AME mutant (34). Non-SUMOylatable mutant 298 
11-HSD2-K266R coexpression was also unable to prevent MR nuclear translocation induced by 100 nM 299 
cortisol, behaving like the loss-of-function mutant R337C (Fig. 6C and 6D). Overnight exposure to 300 
500nM cortisol resulted in MR full nuclear translocation in all conditions (Fig. 6E and 6F). This 301 
demonstrates that 11β-HSD2 capacity to inactivate cortisol can be exceeded by high cortisol levels at the 302 
high end of the physiological range, consistent with previous data (6,44).  303 
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Since lysine residues are the target of other post-translational modifications in addition to SUMOylation, 304 
the effect of the K266R mutant on cortisol-induced MR translocation could reflect other actions, 305 
including acetylation or ubiquitination. To assess this, we co-expressed WT 11-HSD2 with the 306 
established deSUMOylase SENP1. This experiment also resulted in full cortisol-induced MR 307 
translocation, consistent with a SUMOylation-mediated effect on the ability of 11-HSD2 to prevent 308 
cortisol access to MR (Fig. 6G and 6H). It is worth noting that MR has also been described to be 309 
SUMOylated in cells (51). Our experiment indicates that if MR is SUMOylated under our experimental 310 
conditions, SENP1-mediated removal of SUMO does not prevent cortisol-induced receptor nuclear 311 
translocation. 312 
We next investigated the kinetics of cortisol-induced nuclear translocation in living COS-7 cells by 313 
imaging MR subcellular dynamics for the first hour after 100 nM cortisol addition. We ran time-lapse 314 
experiments in cells co-transfected with MR-147-GFP with or without WT 11-HSD2, AME mutant 315 
R337C or non-SUMOylatable mutant K266R. All 11-HSD2 constructs used were CFP-tagged. Images 316 
were taken every two minutes up to 60 minutes after ligand addition and the ratio of nuclear MR was 317 
calculated for every frame. Full cortisol-dependent MR nuclear translocation was achieved approximately 318 
50 minutes after ligand addition (Fig. 7). As expected, WT HSD2 prevented nuclear import (< 10% of the 319 
receptor translocated over the time period). MR translocation in the presence of AME mutant R337C or 320 
non-SUMOylatable mutant K266R, was indistinguishable from the control MR condition (Fig. 7). These 321 
data are consistent with subcellular localization after overnight treatment (Fig. 6C and 6D), suggesting 322 
that 11β-HSD2 ability to prevent cortisol-induced MR translocation is regulated by SUMOylation of 323 
lysine 266. 324 
11β-HSD2-K266R decreases cortisol- but not aldosterone-dependent MR transcriptional response  325 
We then tested whether MR-mediated gene transactivation is affected by 11β-HSD2 SUMOylation. MR 326 
activity was assessed in COS-7 cells by cotransfecting the receptor with a luciferase reporter gene under 327 
the control of a promoter with two glucocorticoid-response elements (GRE2X). We treated cells 328 
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overnight with increasing doses of cortisol in the presence or absence of the different 11β-HSD2 329 
constructs. MR cortisol-dependent transactivation curve showed an EC50 of 40 nM (Fig. 8A). AME 330 
mutants 11-HSD2-R337C or R213C did not alter cortisol potency to elicit MR-dependent 331 
transactivation, presenting an EC50 of 32-44 nM, as expected for loss-of-function constructs. The presence 332 
of WT 11-HSD2 produced the expected decrease in cortisol potency and MR maximal response, with an 333 
EC50 of approximately 2 µM, two orders of magnitude higher than cortisol EC50 for MR. Surprisingly, 334 
non-SUMOylatable mutant 11-HSD2-K266R also decreased cortisol EC50 (1.4 µM) and MR maximal 335 
response, behaving like WT 11-HSD2 (Fig. 8A). Western blot analysis showed that results of activity 336 
assays are not due to impaired MR expression (Fig. 8C and 8D).  337 
Taking into consideration the experiments described above, it is clear that 11-HSD2-K266R promotes 338 
nuclear MR translocation by cortisol but does not alter its dose-dependence for transactivation (compare 339 
Fig. 6C and 8A). This may suggest that MR is functionally impaired in the presence of 11-HSD2-340 
K266R. Therefore, we tested aldosterone-dependent MR transactivation with the different 11-HSD2 341 
constructs (Fig. 8B). All dose-response curves were superimposed, with an EC50 of approximately 0.1-0.2 342 
nM, as expected for aldosterone (32). This result demonstrates that 11-HSD2-K266R does not impede 343 
per se MR activation.  344 
11β-HSD2 SUMOylation affects cortisol-dependent recruitment of co-activators to MR  345 
To gain insight into the mechanism by which 11-HSD2-K266R prevents cortisol-induced MR 346 
transactivation, we tested the interaction between MR and SRC-1, a well-known co-activator of MR (52). 347 
We cotransfected COS-7 cells with WT MR and SRC1 tagged with an HA epitope. SRC-1 displays a 348 
predominantly nuclear localization both in control and cortisol-stimulated conditions, whereas MR shows 349 
the expected ligand-induced trafficking from cytosol to nucleus (Fig. 9A). To quantitatively assess MR-350 
SRC-1 interaction we used PLA in cells co-expressing these two proteins with CFP-tagged WT 11-351 
HSD2 or K266R mutant. Results show a prominent PLA signal in the nucleus when MR is cotransfected 352 
with SRC-1 and nuclear translocation is promoted by cortisol (Fig. 9B). PLA signal was reduced to ~ 353 
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40% by co-expression of either WT or K266R 11-HSD2 (Fig. 9B and 9C). Non-transfected cells, 354 
omission of either one of the transfected plasmids or no ligand addition resulted in the absence of signal 355 
(Fig. 9B and 9C). To ensure that decreased PLA signals did not arise from altered protein expression 356 
levels we quantified MR, SRC-1 and 11-HSD2 abundance by western blot. This experiment showed that 357 
co-expression of the three different proteins did not affect their relative levels (Fig. 9D and 9E). These 358 
results demonstrate that efficient interaction of MR with SRC-1 is impaired not only by the presence of 359 
active 11-HSD2 (which decreases MR nuclear translocation through cortisol inactivation) but also by 360 
the non-SUMOylatable mutant K266R.   361 
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Discussion  362 
Our results show that 11-HSD2 is modified by SUMOylation, with a key conjugation site at residue 363 
K266, which is part of a canonical consensus SUMO-conjugation site. The post-translational modification 364 
likely affects a small percentage of the total cellular protein. This does not preclude an effect on the 365 
biology of 11-HSD2, since it is a common observation that a small fraction of steady-state 366 
SUMOylation frequently has important consequences on the total cellular pool of the modified protein 367 
(48). This idea is reinforced by the fact that SENP1 co-expression with WT 11-HSD2 reproduces the 368 
effect seen with mutant K266R. The implication is that SUMO modification likely alters substrate 369 
proteins long after de-conjugation, perhaps by modifying the protein environment where they reside. This 370 
may have implications for the functional observations reported in this work, as we shall discuss below. 371 
The effect of K266 modification on 11-HSD2 enzymatic activity appears to be mild, with a 30% 372 
decrease in Vmax that is not attributable to decreased protein expression. According to structural 373 
homology modeling using as template the crystal structure of 11-HSD1 (46) or 17-HSD1 (53), residue 374 
K266 lies exposed to the surface of the enzyme (Fig 1B). This area is not directly involved in ligand or 375 
cofactor binding regions and does not form part of the enzyme dimerization interphase. Therefore, it is 376 
not surprising that, unlike the AME mutations affecting those regions (53), SUMOylation at residue K266 377 
does not dramatically alter enzyme activity. On the other hand, the effect of mutant K226R is reminiscent 378 
of a mutation in a nearby residue, R279C, which produces a mild form of AME and displays a reduction 379 
of approximately 33% in Vmax without changes in Km (54). Therefore, it is clear that even a rather small 380 
change in enzyme kinetics not affecting Km is able to diminish the efficiency of 11-HSD2 to prevent 381 
glucocorticoid-induced MR activation.  382 
Despite only mild effect on enzyme kinetics, the consequence of K266R mutation or enzymatic SUMO 383 
de-conjugation on the ability of cortisol to translocate MR to the nucleus is striking. It is clear that 384 
regardless of measurable enzymatic activity, only 11-HSD2 that can be SUMOylated appears to be able 385 
to prevent cortisol from inducing MR translocation to the nucleus. However, what is even more surprising 386 
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is that MR translocated under those conditions (lack of 11-HSD2 SUMOylation at residue K266) does 387 
not increase transactivation of a target promoter, indicating that there is a strong dissociation between MR 388 
subcellular localization and activity. To better understand the relationship between MR nuclear 389 
translocation and activity, we generated combined plots where both parameters can be visualized together 390 
(Fig. 10). This analysis clearly shows that MR ligand-dependence for nuclear translocation is left-shifted 391 
when compared to ligand-dependence for transactivation, particularly in the case of cortisol, both in the 392 
absence or presence of 11-HSD2 (compare Fig. 10B and 10C). Lack of SUMOylation in 11-HSD2-393 
K266R makes the difference in ligand-dependence of both processes even more prominent (Fig. 10D). In 394 
fact, data obtained in vivo already suggests this difference.  In a detailed study examining subcellular 395 
localization of MR and GR in rat kidney under different corticosteroid circulating levels, Ackermann et 396 
al. (55) provided evidence to suggest that 11-HSD2 is sufficient to prevent glucocorticoid-induced GR 397 
translocation to the nucleus, but not MR. Therefore, under physiological conditions, enough 398 
glucocorticoids escape 11-HSD2 action to translocate MR to the nucleus, but not to overly activate the 399 
receptor and produce excessive Na+ reabsorption. This fits well with data showing that under 400 
physiological conditions 11-HSD2 activity cannot prevent most of epithelial MR being occupied by 401 
glucocorticoids (56), but somehow is able to lock glucocorticoid/MR complexes in an inactive state (57). 402 
It has been proposed that 11-HSD2-dependent production of NADH could be involved in this 403 
phenomenon. According to this hypothesis, decreased 11-HSD2 activity would reduce NADH cellular 404 
levels and consequently unlock glucocorticoid/MR activity. It may be that 11-HSD2 SUMOylation 405 
alters the coupling of metabolic processes with glucocorticoid-dependent MR translocation, although our 406 
data does not allow assessing this possibility.  407 
Taken together, our data suggests that lack of 11-HSD2 SUMOylation dissociates MR subcellular 408 
localization and activity, allowing cortisol-induced nuclear translocation without generating the 409 
conformation necessary to recruit transcriptional co-activators. We speculate that 11β-HSD2 may be 410 
interacting directly or indirectly with MR, allowing a cortisol-mediated conformational change of the 411 
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receptor that participates in its activation and depends on previous 11-HSD2 modification by 412 
SUMOylation. This would be in agreement with the proposed function of SUMOylation of altering the 413 
environment where the modified protein interacts even after removal of SUMO (48). Could SUMOylation 414 
alter the proposed physical interaction between MR and 11-HSD2, previously suggested in the literature 415 
(6)? This hypothesis implies that adequate interaction between MR and 11-HSD2 is necessary for the 416 
correct cortisol-induced conformational change of the receptor required to recruit transcriptional co-417 
activators. In the absence of SUMOylation, this interaction would be altered, decreasing MR 418 
transcriptional efficiency, but increasing its ability to translocate to the nucleus. Based on this idea, we 419 
checked whether we could detect direct interaction between MR with 11-HSD2 by PLA, but the results 420 
were negative (data not shown1). This suggests that MR and 11-HSD2 may not closely interact in the 421 
cell, although the result does not preclude the possibility that both proteins are part of a larger complex 422 
and that SUMOylation of 11-HSD2 alters the nature of it.  423 
A different explanation for our data could be based on a compartmentalization of the effects of 11-HSD2 424 
on cortisol concentration in the cell. Under this scenario, lack of 11-HSD2 SUMOylation would change 425 
MR subcellular localization, shifting it towards the nucleus, but nuclear MR would still be depleted of 426 
cortisol because of the enzymatic activity of 11-HSD2. For instance, it is conceivable that 11-HSD2 427 
SUMOylation could place the enzyme near the nuclear pore, creating a low-cortisol nanodomain. SUMO-428 
dependent targeting of proteins to the nuclear pore localization has been previously described  (58). 429 
Disruption of this localization could favor MR nuclear localization without changing the bulk 430 
concentration of cortisol in the cell. Further work will be needed to address this hypothesis. 431 
It remains to be explained why the dissociation between cortisol-dependent nuclear localization and 432 
transcriptional activity is larger than that detected with aldosterone (Fig. 10A and 10B). It has been 433 
                                                        
1 In addition, one of us (A.O.) has also performed two-hybrid assays and co-IP experiments that failed to see a direct 
interaction between MR and 11ß-HSD2. A putative bridging protein may exist but has not been identified yet. 
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demonstrated that cortisol and aldosterone induce differential conformational changes in MR upon 434 
binding. For instance, both agonist differ in their ability to induce interdomain interactions between the 435 
NH2- and COOH-terminal domains of MR (59). We suggest that aldosterone ability to stabilize the ligand 436 
binding domain of the receptor is enough to allow the correct conformational change, regardless of 437 
previous functional or physical interaction with 11-HSD2, whereas cortisol is unable to do so, due in 438 
part to the higher off-rate previously reported (44) and to the influence of non-SUMOylated 11-HSD2.  439 
In summary, we have shown that 11-HSD2 is SUMOylated and that this modification mainly takes place 440 
at residue K266. Mutation of this residue mildly affects enzyme activity by slightly enhancing substrate 441 
affinity and lowering Vmax, but dramatically alters 11-HSD2 ability to prevent cortisol-induced MR 442 
nuclear translocation. Interestingly, although impairing 11-HSD2 SUMOylation enhances cortisol-443 
dependent MR nuclear translocation, the amount of MR/co-activator complexes formed remains 444 
unaltered, resulting in the same transcriptional activity. This phenomenon uncovers a complex and 445 
SUMOylation-regulated functional role of 11-HSD2 that dissociates glucocorticoid-dependent MR 446 
subcellular localization from transcriptional activity.   447 
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Figure legends 617 
Figure 1. Prediction of SUMOylation sites in 11β-HSD2 by in silico analysis. A, Sequence alignment 618 
around the highly conserved lysine residue (shaded) that forms part of a canonical SUMOylation 619 
consensus sequence, -K-x-D/E (where  is a large hydrophobic residue and x is any amino acid), which 620 
is indicated above the alignment. The box highlights those species where the SUMOylation consensus 621 
sequence is found. *, Residues conserved in every species examined; :, positions with conservative amino 622 
acid substitutions; ., partially conserved residues. B, Homology model of mouse 11-HSD2 based on the 623 
crystal structure of 11-HSD1 (46) showing the predicted position of K266. K266 is located in a -sheet 624 
and is facing the aqueous solution. The model shows the cofactor bound to the structure. The area formed 625 
by parallel -sheets defines a core region conserved among all short-chain dehydrogenase reductases. 626 
K266 is not within this core and unlikely interferes with catalytic activity.  627 
Figure 2. 11β-HSD2 is SUMOylated mainly at residue K266. A, subcellular localization of FLAG-628 
tagged WT 11-HSD2 and non-SUMOylatable mutant K266R. B, representative images of proximity 629 
ligation assay (PLA) results examining the interaction of FLAG-tagged 11-HSD2-WT or non-630 
SUMOylatable mutant K266R with YFP-SUMO1 in the absence or presence of deSUMOylate SENP1. 631 
C) Quantitative analysis of PLA signals. Bars represent the average number of puncta/cell area ± S.E. (n = 632 
20 cells per condition). Negative controls consisted on analysis of non-transfected cells (N.T.) or leaving 633 
out either 11-HSD2-WT or YFP-SUMO1 from the transfection mix. n.s., no significant difference; ***, 634 
p< 0.001; one-way ANOVA followed by Dunn’s multiple comparisons test. 635 
Figure 3. 11β-HSD2 SUMOylation analyzed by pull-down followed by western blot. Cells were 636 
transfected with the indicated combinations of FLAG-tagged WT or mutant 11-HSD2 and YFP-SUMO. 637 
Negative control consisted on omission of 11-HSD2 in the transfection mix or transfection with empty 638 
plasmids (N.T.). Cell lysates were analyzed with anti--actin (-actin), anti-11-HSD2 and anti-YFP 639 
antibodies (panel A). Immunoprecipitation was performed with an anti-FLAG antibody and products were 640 
analyzed with anti-GFP antibody to detect YFP-SUMO (panel B) or anti-11-HSD2 antibody (panels C 641 
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and D). Note that panels C and D correspond to different portions of the same blot with different exposure 642 
times to obtain optimal signals. Arrowheads mark the migration of molecular mass markers (values in 643 
kDa).  644 
Figure 4. 11-HSD2-K266R mutant displays normal protein abundance. A, representative western 645 
blot of 11-HSD2 WT and mutant expression in COS-7 cells. NT, non transfected cells. The same blot 646 
was consecutively probed with anti-11-HSD2 and anti-GAPDH antibodies. Arrowheads mark the 647 
migration of molecular mass markers (values in kDa). B, quantitative analysis of western blots detecting 648 
expression of 11-HSD2 variants. Bars represent the average  SE of 3-4 independent experiments. n.s., 649 
no significant difference; *, p< 0.05; one-way ANOVA followed by Dunn’s multiple comparisons test. 650 
Figure 5. Non-SUMOylatable mutation K266R alters 11-HSD2 enzyme kinetics. COS-7 cells were 651 
transfected with WT 11-HSD2 or non-SUMOylatable mutant K266R. After 24h in charcoal-stripped 652 
serum-supplemented DMEM, cells were treated with indicated time and cortisol concentration. Steroids 653 
in culture medium were quantified by LC-MS/MS. A) Percentage conversion of 300 nM cortisol to 654 
cortisone in non-transfected cells (N.T.) or in cells transfected with WT 11-HSD2. Linear regression 655 
was used to fit data points to a linear equation. B) WT and mutant11-HSD2 enzyme kinetics. 656 
Transfected cells were treated with increasing cortisol concentrations for 30 min. Data points represent 657 
average values  SE (N=3 independent experiments, conducted in duplicate) and were fitted to the 658 
Michaelis-Menten equation.  659 
Figure 6. 11β-HSD2 SUMOylation is essential for the ability of the enzyme to prevent cortisol-660 
induced MR nuclear translocation. Quantitative analysis and representative images of YFP-tagged MR 661 
subcellular localization in COS-7 cells expressed alone or cotransfected with CFP-tagged 11-HSD2 662 
variants  (WT, non-SUMOylatable mutant K266R or AME mutant R337C) in the absence of ligand (A 663 
and B), in cells treated with 100 nM cortisol (C and D) or in cells treated with 500 nM cortisol (E and F). 664 
Values represent the average percentage of cells in each category from the total amount of cells scored in 665 
three independent experiments (N, exclusive nuclear localization; N C, predominant nuclear localization; 666 
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N C, even distribution throughout cytosol and nucleus; N C, predominant cytosolic localization; C, 667 
exclusive cytosolic localization). MR distribution was also tested in cells cotransfected with 11-HSD2 in 668 
the presence or absence of the deSUMOylase SENP1 and treated with 100 nM cortisol (G and H).  669 
Figure 7. Cortisol-induced MR nuclear translocation kinetic in the presence of 11β-HSD2 variants. 670 
COS-7 cells were co-transfected with the indicated combinations of GFP-tagged MR and CFP-tagged WT 671 
or 11-HSD2 mutants. Untreated cells were placed under the confocal microscope in Ringer´s medium 672 
and treated with 100 nM cortisol. A, time course analysis of MR nuclear translocation after cortisol 673 
addition (time 0). Images were recorded every two minutes. Values represent average ± SE (N = 7-9) 674 
percentage nuclear fluorescence intensity versus total cellular fluorescence (F). Data points were fitted to 675 
Boltzmann sigmoidal curves. B, representative images of cortisol-induced MR nuclear translocation by 676 
100 nM cortisol. T, time in minutes after cortisol addition. 677 
Figure 8. Cortisol-induced MR nuclear translocation in the presence of non-SUMOylatable 11β-678 
HSD2 results in reduced receptor activity. COS-7 cells were co-transfected with the indicated 679 
combinations of YFP-tagged MR and CFP-tagged WT or mutant 11-HSD2, GRE2X-luciferase and 680 
CMV-Renilla reporters. After 24h in charcoal-stripped serum-supplemented DMEM, cells were treated 681 
with the indicated dose of cortisol or aldosterone overnight and firefly and Renilla luciferase activities 682 
were determined using the Dual-Glo kit (Promega). Individual points represent the average  SE (N = 3) 683 
firefly/Renilla values normalized to the maximum activity for each construct in cells stimulated with 684 
cortisol (A) or aldosterone (B). Data points were fitted to a variable slope model (four parameters). C, 685 
representative western blots of MR expression in COS-7 cells. NT, non-transfected cells. The same blot 686 
was consecutively probed with anti-MR and anti-GAPDH antibodies. Arrowheads mark the migration of 687 
molecular mass markers (values in kDa). D, quantitative analysis of western blots detecting expression of 688 
MR. Bars represent the average  SE of three independent experiments. *, p< 0.05, one-way ANOVA 689 
followed by Dunn’s multiple comparisons test. 690 
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Figure 9. 11-HSD2- K266R expression impairs MR interaction with SRC-1 coactivator after 691 
cortisol treatment. COS-7 cells were co-transfected with the indicated combinations of WT MR, HA-692 
tagged SRC-1 and CFP-tagged 11-HSD2 constructs. A, subcellular localization of MR and SRC-1 693 
before and after 100 nM cortisol treatment. B, representative images of proximity ligation assay (PLA) 694 
results examining the nuclear interaction between MR and SCR-1 after 100 nM cortisol treatment in the 695 
absence or presence of 11-HSD2-WT or -K266R mutant. PLA was performed with monoclonal anti-HA 696 
and polyclonal anti-MR antibodies. C, quantitative analysis of PLA signals. Bars represent the average 697 
number of puncta/cell area ± S.E. (n = 20-25 cells per condition). Negative controls consisted on analysis 698 
of non-transfected cells, leaving out either MR-WT or SRC-1 plasmids from the transfection mix or 699 
omission of cortisol treatment. N.T., non-transfected cells. ***, p< 0.001, one-way ANOVA followed by 700 
Dunn’s multiple comparisons test. D, representative western blot of MR, SRC-1 and 11-HSD2 WT and 701 
mutant expression when co-transfected in COS-7 cells in the indicated combinations. NT, non transfected 702 
cells. Arrowheads mark the migration of molecular mass markers (values in kDa). E, quantitative analysis 703 
of western blots detecting expression of MR, SRC-1 and 11-HSD2 variants. Bars represent the average 704 
 SE of 3 independent experiments. 705 
Figure 10. Ligand dose-dependence regulation of MR nuclear translocation and activity. Plots 706 
simultaneously represent relative luciferase activity and percentage nuclear MR localization for the 707 
indicated ligand concentration and in the presence or absence of WT or mutant 11-HSD2. Data points 708 
were fitted to a variable slope model (four parameters). Individual data points or bars represent mean ± 709 
SE. Nuclear localization data at 0, 100 and 500 nM cortisol comes from Fig. 6. Luciferase activity data 710 
comes from Fig. 8.  711 
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Peptide/protein target
MR
MR
11b-HSD2
GFP
GAPDH
b-Actin
HA epitope
FLAG epitope
IgG heavy chains and all classes of immunoglobulin light chains from rabbit
IgG heavy chains and all classes of immunoglobulin light chains from mouse
Purified immunoglobulin fractions from normal rabbit serum
Purified immunoglobulin fractions from normal mouse serum
Antibody Table
Antigen sequence (if known) Name of Antibody
Rat mineralocorticoid receptor amino acids 365-381 rMR365 4D6
Human mineralocorticoid receptor amino acids 1-300 H-300
Human 11b-HSD2 amino acids 261-405 H-145
Recombinant full length GFP protein Anti-GFP 
Full length native protein from human erythrocytes Anti-GAPDH
SGPSIVHRKCF AC-40
CYPYDVPDYASL HA.11 clone 16B12
DYKDDDDK Anti-FLAG®  M2
Alexa Fluor® 594 Goat Anti-Rabbit IgG (H+L) Antibody
Alexa Fluor® 594 Goat Anti-Mouse IgG (H+L) Antibody
Amersham ECL Mouse IgG, HRP-Linked Whole Ab
Amersham ECL Rabbit IgG, HRP-Linked Whole Ab 
Manufacturer, catalog #, and/or name of individual providing the antibody
Dr. Celso Gomez-Sanchez (antibody available through the Developmental Studies Hybridoma Bank, product # rMR365 4D6)
Santa Cruz Biotechnology, catalog # sc-11412
Santa Cruz Biotechnology, catalog # sc-20176
Abcam, catalog # 290
Abcam, catalog # 9484
Sigma-Aldrich, catalog # A3853
Covance, catalog # MMS-101R
Sigma Aldrich, catalog #F-1804
Life Technologies (Molecular Probes), catalog # A-11037
Life Technologies (Molecular Probes), catalog # A-11005
GE Healthcare (Amersham), catalog # NA931
GE Healthcare (Amersham), catalog # NA934
Species raised in; monoclonal or 
polyclonal
Dilution used
Mouse monoclonal Undiluted hydridoma supernatant (WB)
Rabbit polyclonal 1:200 (IF and PLA)
Rabbit polyclonal 1:600 (WB)
Rabbit polyclonal 1:3000 (WB); 1:1000 (IF); 1:200 (PLA)
Mouse monoclonal 1:10000 (WB)
Mouse monoclonal 1:1000 (WB)
Mouse monoclonal 1:1000 (WB); 1:1000 (IF); 1:200 (PLA)
Mouse monoclonal 1:150 (IP)
Goat polyclonal 1:500 (IF)
Goat polyclonal 1:500 (IF)
Donkey polyclonal 1:20000 (WB)
Sheep polyclonal 1:20000 (WB)
Research Resource Identifier (RRID)
AB_2267538
AB_2155949
AB_2233199
AB_303395
AB_307274
AB_262137
AB_291262
AB_262044
AB_2534095
AB_141372
AB_772210
AB_772206
